9 Meters Biopharma Inc. announced that the United States Adopted Names (USAN) Council has officially designated the Company's long-acting injectable glucagon-like peptide-1 (GLP-1) receptor agonist drug candidate for short bowel syndrome, NM-002, as "vurolenatide". Unlike other agents in development for short bowel syndrome, vurolenatide is distinct not only from other GLP-1 agonists, but especially from GLP-2 agonists. As demonstrated recently in Phase 1b/2a study, its potential includes rapid onset, sustained duration, and improvement in total stool output (TSO)-which mitigates the chronic diarrhea that profoundly impacts the quality of life for SBS patients.